论文部分内容阅读
目的:研究慢性粒细胞白血病(CML)患者外周血中Th22细胞的比例、相关转录因子芳香烃受体(AHR)的表达水平及细胞因子IL-22的浓度,探讨Th22细胞在CML免疫机制中的作用。方法:应用流式细胞术检测Th22细胞在33例CML患者(初诊15例,伊马替尼治疗后的CML-CP 18例)外周血中的比例,实时荧光定量PCR技术检测CML患者Th22相关转录因子AHR mRNA的表达水平,ELISA法检测细胞因子IL-22的浓度。同时以15例正常者作为对照。结果:CML初诊患者外周血的Th22细胞比例(0.43%±0.23%)明显低于伊马替尼治疗后的CML-CP患者(3.19%±1.76%,P<0.05)和对照者(2.58%±0.98%,P<0.05)。CML初诊患者外周血单个核细胞的AHR基因转录水平(0.212 9±0.174 6)与伊马替尼治疗后的CML-CP患者(0.817 1±0.388 7,P<0.05)和对照者(0.468 1±0.180 4,P<0.05)比较均明显降低。伊马替尼治疗后的CML-CP患者外周血AHR mRNA表达水平较对照者显著升高(P<0.05)。CML-CP患者的外周血IL-22浓度较对照者显著升高[(100.94±18.48)pg/ml∶(85.14±13.46)pg/ml,P<0.05]。Th22细胞的比例与CML患者外周血白细胞计数及BCR-ABL%均呈负相关。结论:Th22细胞下调,Th22免疫功能受损可能有助于CML的发生和发展。
Objective: To investigate the Th22 cells in peripheral blood of patients with chronic myeloid leukemia (CML), the expression level of related transcription factor aromatic receptor (AHR) and the concentration of cytokines IL-22, and to explore the Th22 cells in CML immune mechanism effect. Methods: Flow cytometry was used to detect the percentage of Th22 cells in peripheral blood of 33 CML patients (15 newly diagnosed CML-CML patients after treatment with imatinib). The levels of Th22-related transcription in CML patients were detected by real-time fluorescence quantitative PCR Factor AHR mRNA expression levels, ELISA method to detect the concentration of cytokines IL-22. At the same time, 15 normal controls were used as control. Results: Th22 cells in peripheral blood of newly diagnosed CML patients (0.43% ± 0.23%) were significantly lower than those of CML-CP patients (3.19% ± 1.76%, P <0.05) after imatinib treatment and 2.58% ± 0.98%, P <0.05). The level of AHR gene transcription in peripheral blood mononuclear cells of newly diagnosed CML patients (0.212 9 ± 0.174 6) was significantly higher than that of CML-CP patients (0.817 1 ± 0.388 7, P <0.05) after imatinib treatment and 0.468 1 ± 0.180 4, P <0.05) were significantly lower. The expression of AHR mRNA in peripheral blood of CML-CP patients after imatinib treatment was significantly higher than that of the control (P <0.05). The level of IL-22 in peripheral blood of patients with CML-CP was significantly higher than that of controls ([100.94 ± 18.48] pg / ml: (85.14 ± 13.46) pg / ml, P <0.05]. Th22 cell ratio and CML patients with peripheral blood leukocyte count and BCR-ABL% were negatively correlated. Conclusion: Down-regulation of Th22 cells and impaired Th22 immune function may contribute to the occurrence and development of CML.